The global hemophilia market is undergoing a significant transformation, driven by novel drug approvals, expanding gene therapy options, and growing disease awareness. Within this space, the hemophilia A market stands out as the largest and most closely watched segment, given its higher prevalence and the rapid pace of therapeutic innovation targeting factor VIII deficiency.
Hemophilia A Market Size and Forecast
The hemophilia A market size across the seven major markets (7MM) — the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan — was valued at USD 12,918 million in 2025 and is projected to reach USD 16,756 million by 2034, growing at a CAGR of 2.9%. The United States represents the single largest contributor, accounting for roughly USD 5,920 million in 2024, with EU4 and the UK together making up about 58% of the 7MM diagnosed prevalent population. Japan’s market stood at approximately USD 1,150 million in 2024. This steady hemophilia market forecast reflects both rising diagnosis rates and the introduction of higher-priced, longer-acting therapies.
Hemophilia A Epidemiology and Epidemiology Forecast
Hemophilia A epidemiology data shows the total diagnosed prevalent population in the 7MM was nearly 49,500 cases in 2024, expected to rise modestly to around 50,000 by 2034. The hemophilia epidemiology picture varies by severity — in the US, roughly 35% of cases are mild, 15% moderate, and 50% severe. Inhibitor status also matters: about 2,000 US cases involved inhibitors versus 12,700 non-inhibitor cases in 2024. This hemophilia A epidemiology forecast underscores the importance of segmenting patients by age, severity, and inhibitor status when evaluating unmet needs. Hemophilia B, a related but distinct bleeding disorder caused by factor IX deficiency, is also tracked alongside hemophilia A, and the hemophilia B market benefits from several of the same non-factor therapies now approved for dual indications.
Hemophilia A Treatment and Drug Landscape
Hemophilia A treatment has historically centered on factor VIII replacement, evolving from plasma-derived products to recombinant options. The recombinant factor VIII market includes established products such as ADVATE, KOGENATE FS, ELOCTATE, JIVI, and ALTUVIIIO, alongside plasma-derived agents like HEMOFIL-M and MONOCLATE-P. For patients who develop inhibitors, HEMLIBRA has become a first-line prophylactic option. The hemophilia A treatment market has recently expanded beyond factor replacement with non-factor therapies: Pfizer’s HYMPAVZI (marstacimab-hncq), an anti-TFPI therapy approved in October 2024, and Sanofi’s QFITLIA (fitusiran), an antithrombin-lowering siRNA therapy approved in March 2025 for both hemophilia A and B patients aged 12 and older, with or without inhibitors.
Separately, acquired hemophilia A, a rare condition where the body develops antibodies against its own factor VIII, is managed differently — OBIZUR (susoctocog alfa) is specifically indicated for bleeding episodes in this population, representing a niche but important corner of the acquired hemophilia A treatment market.
Hemophilia A Gene Therapy Market
Perhaps the most transformative development in the hemophilia gene therapy market is BioMarin’s ROCTAVIAN (valoctocogene roxaparvovec), an AAV5-based gene therapy approved by the FDA in June 2023 for adults with severe hemophilia A. It offers a one-time infusion designed to enable long-term endogenous factor VIII production, potentially freeing patients from chronic prophylaxis. The broader hemophilia A gene therapy pipeline includes Pfizer’s giroctocogene fitelparvovec, which reported strong Phase III results in July 2024, with 84% of participants maintaining over 5% FVIII activity at 15 months post-infusion.
Hemophilia A Pipeline and Drugs Market Outlook
The hemophilia A pipeline remains robust, with companies like Novo Nordisk (Mim8, denecimig, ALHEMO), Roche/Chugai (NXT007), Sangamo Therapeutics, ASC Therapeutics (ASC-618), and Ultragenyx (DTX201) advancing candidates through Phase I to Phase III trials. Novo Nordisk’s Mim8 is a next-generation bispecific antibody in Phase III development, offering once-weekly or once-monthly subcutaneous dosing for patients with and without inhibitors. This continued innovation is expected to reshape the hemophilia drugs market and the broader hemophilia treatment drugs market over the next decade.
US Hemophilia Treatment Market and Broader Bleeding Disorders Landscape
The US hemophilia treatment market continues to lead globally due to early access to novel approvals, favorable reimbursement pathways, and a high diagnosed patient pool. More broadly, the bleeding disorders treatment market, encompassing both hemophilia A and B along with rarer clotting deficiencies, is benefiting from parallel advances in gene therapy, RNAi technology, and bispecific antibodies. As factor VIII deficiency and its treatment options continue to evolve, factor VIII deficiency treatment strategies are shifting toward less frequent dosing, improved safety profiles, and options that work regardless of inhibitor status — pointing to a more personalized, less burdensome future for patients living with hemophilia A.
Latest Reports Offered by Delveinsight
pheochromocytomas/paragangliomas market | pork tapeworm infection market | post-operative nausea & vomiting market | powered surgical instrument market | precocious puberty market | primary progressive aphasia market | pro-opiomelanocortin pomc deficiency obesity & leptin receptor lepr deficiency obesity market | pseudoxanthoma elasticum market | psoriasis vulgaris market | psoriatic arthritis market | ptosis market | pulmonary hypertension associated with interstitial lung disease market | pulmonary sarcoidosis market | pyruvate kinase deficiency market | renal insufficiency market | restless legs syndrome market | rett syndrome market | richter syndrome market | rosai-dorfman disease market | sacral nerve stimulator market | scabies market | schistosomiasis market
scleritis market | secondary progressive multiple sclerosis market | sensorineural hearing loss market | severe hypoglycemia market | shigella infections market | short bowel syndrome drug market | sialorhhea market | singapore healthcare outlook report | single ventricle heart disease market |
About Delveinsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk